Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKelso Grp Hldg Regulatory News (KLSO)

Share Price Information for Kelso Grp Hldg (KLSO)

Share Price is delayed by 15 minutes
Get Live Data
3.30    0.05 (1.59%)
Bid:
3.10
Ask:
3.30
Spread: 0.20 (6.452%)
Market Cap: £15.31m
KLSO Live PriceLast checked at - London Stock Exchange

Intraday Kelso Grp Hldg Share Chart

Investment in THG Plc Update

13 Jul 2023 07:00

RNS Number : 8594F
Kelso Group Holdings PLC
13 July 2023
 

 

Kelso Group Holdings Plc ("Kelso' or the "Company")

 

Investment in THG Plc ("THG") Update

 

 

Kelso, the main market listed investment company, updates its shareholders on its investment in THG Plc ("THG"). As previously announced in its Trading Update on 12 July 2023, Kelso confirmed its ownership of 8.0 million shares in THG, by way of ordinary shares and CFDs.

 

Kelso is pleased with the significant progress made by THG during 2023, including its recent positive trading statement, with management expecting H1 EBITDA to be approximately 41% up year on year. This progress has been helped by the external tailwinds of the significant whey price reduction which should help profitability particularly in H2. However, the significant non trading internal progress achieved should not be underestimated; improved communication to the stock market; improved corporate governance with new NEDs, early release of the golden share and reiterated commitment to joining the premium index which we hope will occur H1 2024.

 

The one-year anniversary of the announcement of the THG 'Separation' is later this month. The Separation occurred almost two years after the IPO and importantly allows each business division to be independently managed and reported on. It also facilitates possible third-party investment into any of the divisions and potentially for any of the divisions to be sold partially or in full. Importantly, Separation therefore gives THG significant strategic optionality, and we welcome management's openness and desire to explore these opportunities.

 

Kelso continues to believe this approach encourages stock market analysts to value THG on a sum of the parts basis, given the distinct nature of the various divisions. It is pleasing to see this change gradually occurring in the analyst community and we believe this will ultimately lead to the stock market better appreciating the fundamental value of THG, shifting away from pure e-commerce benchmark valuations. Liberum, the independent broker, continues to re-emphasise its 225p target value, over two times the current share price, but it is also encouraging to see other analysts increasingly refer in their research to higher potential price targets centred around the sum of the parts valuation.

 

In particular, we believe that THG's Nutrition division with its main brand of MyProtein should be valued as a global consumer brand, given near $1bn sales, double-digit EBITDA margins and its increased product innovation in the current year. This division alone continues, in our view, to be worth more than the market capitalisation of THG. Kelso's RNS on 21 April 20232 highlighted this value and the names of some of the global brands that are increasingly shifting the balance of their product portfolios away from sugar and chocolate products to more healthy and nutritional ones. This is made clear when the 131 global consumer product companies, with an average market capitalisation of £85.3bn, that we believe could potentially have strategic interest in this division, trade on an average EV/Sales of 4.4x. THG remains valued on an EV/Sales of c.0.5x.

 

Centred around the potential value of MyProtein, Kelso has been pleased to see two further industry developments in the last few weeks. First of all, on 5 July 2023, Mars Wrigley ("Mars") announced the acquisition of Kevin's Natural Foods for $800m, a business founded in 2019. Kevin's Natural Foods reportedly generated approximately $140m of revenue in 2022 up from approximately $100m in 2021, which implies a 5.7x historical sales multiple. This sales multiple is not dissimilar to other recent sales multiples on acquisitions in the nutrition sector. Secondly, we note the announcement on 22 June 2023 by Tesco reaffirming its commitment to support healthy affordable diets. Tesco announced in this statement its target of boosting sales of healthy products to 65% as a proportion of total sales by 2025. Kelso highlighted in its RNS on 21 April 20232 date about the global investment institutions demanding that food brands declare what % of their product portfolio are 'healthy'. Kelso believes that the combination of retailers such as Tesco targeting healthier products coupled with institutional investors equally wanting to understand the healthiness of the product portfolios of the global food brands better should leave THG's leading nutrition brand MyProtein in a strategically advantageous position as it further expands globally.

THG appears to be in a much steadier and improved position year on year. With THG's net debt to EBITDA ratio now approaching 1.0x, Kelso would like to see THG buying back some of its equity or debt demonstrating the improved confidence that they have shown in recent announcements.

 

Kelso continues to encourage THG to deliver on a sum of the parts realisation and is very pleased that the company are open to driving this change forward. Kelso is looking forward to the interim results of THG in September with hopefully some corporate strategy update which we hope will serve to further explain and support why the recent Apollo bid was rejected.

 

1Nestle, Coca Cola, Pepsi, Mondelez, Mars*, Hershey, Ferrero*, General Mills, Lotus Bakeries, Monster, Kraft Heinz, Keurig Dr Pepper, Danone *Denotes private

2https://www.londonstockexchange.com/news-article/KLSO/update-on-thg-investment-and-placing/15925580

 

For further information please contact:

Kelso Group Holdings plc

+44 (0) 75 4033 3933

John Goold, Chief Executive Officer

Mark Kirkland, Chief Financial Officer

Jamie Brooke, Chief Investment Officer

Zeus (Broker)

+44 (0) 20 3829 5000

Nick Cowles, Ed Beddows (Investment Banking)

Ben Robertson (Corporate Broking)

 

About Kelso:

Kelso was established in November 2022 to identify, engage and unlock trapped value in UK listed companies. Through active engagement and alignment with other stakeholders, Kelso aims to effect change where existing shareholders are often unable or unwilling to do so themselves. Kelso is run by John Goold (CEO), Mark Kirkland (CFO and Strategy) and Jamie Brooke (CIO) each of which have over 25 years of experience in the quoted and unquoted UK small and mid-cap market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGPUCGMUPWPGP
12
Date   Source Headline
5th Jun 20267:00 amRNSPortfolio update
28th May 20267:00 amRNSNotice of AGM
22nd May 20267:00 amRNSHolding(s) in Company
14th May 20267:00 amRNSResult of Placing and Subscription
13th May 20267:00 amRNSProposed Placing and Subscription
30th Apr 20267:00 amRNSFY25 Results
27th Apr 20267:00 amRNSNew investment in Filtronic plc
22nd Apr 20265:33 pmRNSHolding(s) in Company
22nd Apr 20265:32 pmRNSHolding(s) in Company
22nd Apr 20265:32 pmRNSHolding(s) in Company
27th Feb 20265:36 pmRNSHolding(s) in Company
23rd Feb 20267:00 amRNSUpdate on Investment: TheWorks.co.uk Plc
20th Feb 20267:00 amRNS-RYellowstone Advisory Presentation
17th Feb 20267:00 amRNSNew investment in CVS Group plc
22nd Jan 20267:00 amRNSUpdate on Investment in NCC Group plc
15th Jan 20269:55 amRNSNotification of Major Holdings
6th Jan 20267:00 amRNSNew investment in Saga plc
17th Dec 20257:00 amRNSResult of Placing and Subscription
16th Dec 20257:00 amRNSUpsizing of Placing and Subscription
15th Dec 20254:35 pmRNSProposed Placing and Subscription
30th Sep 20257:00 amRNSInterim results for six months ended 30 June 2025
25th Jun 20254:17 pmRNSResult of AGM
25th Jun 20257:00 amRNSAGM Trading Update
30th May 20259:06 amRNSNotice of AGM
23rd May 20257:15 amRNSDirector/PDMR Shareholding
16th May 20257:00 amRNSPurchase of Shares & PDMR Shareholding
24th Apr 20257:00 amRNSTransaction in Own Shares
23rd Apr 20257:00 amRNSFY24 Results
27th Nov 20247:00 amBUSHolding(s) in Company
7th Nov 20247:00 amRNSOliver Hemsley Appointment & Selkirk IPO Update
17th Oct 20247:00 amRNSUpdate on Kelso Investments
10th Oct 20245:00 pmRNSComment on THG Plc
1st Oct 20248:00 amRNSListing Rule 9.6.14(1) announcement
30th Sep 20247:00 amRNSInterim results for six months ended 30 June 2024
16th Aug 20247:00 amRNSUpdate on Investment in NCC Group Plc
2nd Aug 20247:00 amRNSUpdate on Investment in NCC
7th Jun 20247:00 amRNSNotification of Major Holdings
4th Jun 20247:00 amRNSNotification of Major Holdings
30th May 20244:00 pmRNSResult of AGM
30th May 20247:00 amRNSAGM Trading Update
21st May 20247:00 amRNSVoting intentions at THG AGM
8th May 202411:44 amRNSConfirmation of Accounts and Notice of AGM
8th May 20247:00 amRNSPosting of Annual Report and Notice of AGM
30th Apr 20247:02 amRNSFurther investment in NCC Group Plc
30th Apr 20247:00 amRNSFull-year results for 12 months ended 31 Dec 2023
4th Apr 20248:00 amRNSNotice of Results
14th Mar 20247:00 amRNSNotification of Major Holdings
14th Feb 20247:01 amRNSNED Appointments to The Works
14th Feb 20247:00 amRNSNotification of Major Holdings
30th Jan 20247:00 amRNSNotification of Major Holdings
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.